Boston, MA 03\/06\/2014 (wallstreetpr) –\u00a0New product launches, particularly in the biopharmaceutical field are a very costly affair. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)<\/b> is aware of this and is coming out with a second public offering to fund its research and development costs.<\/p>\n
\n
Strong pipeline:<\/b><\/p>\n
\n
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is carrying out stability testing of three batches of pimavanserin. These were produced in the third quarter of 2013. Apart from this, the company is also carrying out drug-drug interaction studies. The company also provided updates about the accumulation of data from an extension study as well as the phase 2 trials for Alzheimer’s Disease Psychosis (PDP). The DDI (drug-drug interaction) studies are going on and the company expects to complete them on time. As the patients in the clinical trial were already using several medications, this gave the company real time data to study the effects of its drug and its interaction with other drugs. No adverse reactions have been observed. The phase 3 open label safety extension study is also proceeding as per plan and will continue till pimavanserin is fully commercialized. Over 250 patients have been treated for one year or longer with about 10 patients completing 2 years or more. In fact, one patient has been using the drug for about 8 years now. None of the patients have reacted adversely.<\/p>\n
With this, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is confident of submitting NDA before the end of 2014. The pre-NDA meetings are expected to commence shortly. The company also has had a series of meetings with the regulatory agencies of several EU countries.<\/p>\n
\n
Cash Flow important:<\/b><\/p>\n
\n
With the commercialization phase very near, the company will require ready cash in hand. It has announced the pricing of an underwritten public offering of 6.40 million shares of common stock. It will offer them to the public at a price of $28.50 per share. This offering is expected to result in gross inflows of around $182.4 million in the company. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will be using the proceeds to fund ongoing and future clinical trials as well as general corporate purposes.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/06\/2014 (wallstreetpr) –\u00a0New product launches, particularly in the biopharmaceutical field are a very costly affair. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is aware of this […]<\/p>\n","protected":false},"author":32,"featured_media":16689,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2013,2014],"stock_ticker":[],"class_list":["post-16688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-acadia-pharmaceuticals-inc-nasdaqacad","tag-nasdaqacad","entry"],"acf":[],"yoast_head":"\n